Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials
- PMID: 24881037
- PMCID: PMC4040888
- DOI: 10.3324/haematol.2014.106013
Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials
References
-
- Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005;23(10):2224–32 - PubMed
-
- Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011;29(23):3179–84 - PubMed
-
- Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Inten Med 1995;123(9):656–64 - PubMed
-
- Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8(3):556–62 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
